Safety and immunogenicity of a sarcoid vaccine in horses.
Authors: Jacob O, Hause B, Peters-Smith K, Adam E N, Page A E, Floyd C, Tucker C, Eertink L G, Wang D, Li F
Journal: Journal of equine veterinary science
Summary
Equine sarcoids represent the most prevalent skin tumours in horses and are causally linked to bovine papillomavirus type 1 (BPV1) infection, yet no preventative vaccine currently exists despite the significant welfare and economic burden these lesions impose through treatment difficulties and performance impairment. Researchers administered a recombinant baculovirus vector vaccine expressing BPV1 L1 protein intramuscularly to 10 healthy, sarcoid-free horses on two occasions three weeks apart, with five control horses receiving culture medium, monitoring clinical signs daily and measuring serum neutralising antibody responses using a pseudovirus-based assay. All vaccinated horses tolerated the immunisation exceptionally well with no clinically relevant adverse reactions, and crucially, all 10 developed robust neutralising antibody titres ranging from 40 to greater than 1280 by the pseudovirus assay, whilst pre-vaccination samples and control group sera showed no detectable antibodies. Since neutralising antibodies represent an established correlate of protection against BPV1, these promising results suggest the vaccine could provide meaningful prevention of sarcoid development, potentially transforming management of this common and frustrating condition. For practitioners, whilst protection efficacy in naturally exposed populations and duration of immunity remain to be established through further trials, this represents a significant advance toward controlling a disease that currently limits performance, reduces welfare, and generates substantial treatment costs.
Read the full abstract on PubMed
Practical Takeaways
- •A novel sarcoid vaccine candidate has demonstrated safety and strong immunogenic response in a small equine trial, offering potential future protection against the most common equine skin tumor
- •The vaccine induced consistent antibody responses across all vaccinated horses with a simple two-dose protocol (3-week interval), suggesting feasible practical implementation if field efficacy is confirmed
- •While promising, this is early-stage work; practitioners should await larger field trials and regulatory approval before expecting this vaccine to become available for clinical use
Key Findings
- •A recombinant baculovirus vector vaccine expressing BPV1 L1 protein was safe with no clinically relevant adverse reactions observed in 10 vaccinated horses
- •All 10 vaccinated horses developed neutralizing antibody titers ranging from 40 to >1280 after two intramuscular doses at 3-week intervals
- •Control group horses (n=5) and pre-vaccination sera showed no detectable virus-neutralizing antibodies
- •Robust neutralizing antibody response indicates potential protective efficacy against equine sarcoids, pending field efficacy studies